Sildenafil Brand Ranking

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited

Guangzhou Pharmaceutical Group Baiyunshan Pharmaceutical Factory took 16 years of research and development. In November 2014, the first "Baiyunshan Jinge" product was officially launched. With the creation of a pharmaceutical miracle of sales exceeding 700 million in one year of its launch, it ended foreign pharmaceutical companies. In China's anti-ED market, it has been monopolized for 13 years. In March 2001, sildenafil citrate raw materials and tablets obtained clinical approval for Class I new drugs of the State Food and Drug Administration. In March 2001, Jinge (sildenafil citrate tablets) carried out randomization at the former Peking University People's Hospital, Peking University First Hospital, Peking University Third Hospital, Sun Yat-sen Medical University Third Affiliated Hospital, and Dalian Medical University First Affiliated Hospital. A multicenter clinical study with double-blind and placebo parallel control showed that the "sildenafil citrate tablets" developed by Baiyunshan were safe and effective. In June 2003, sildenafil citrate raw materials and tablets obtained the National Medical Products Administration's Class I new drug certificate. In November 2004, the synthesis process of sildenafil citrate raw material of Baiyunshan Jinge obtained an invention patent; In June 2005, the invention patent for the sildenafil citrate raw material of Baiyunshan Jingo was also authorized.

Jiangsu Yabang Pharmaceutical Group Co., Ltd.

Jiangsu Yabang Pharmaceutical Group Co., Ltd. was founded in 2002 and is headquartered in Changzhou City, Jiangsu Province. It is a large comprehensive pharmaceutical group integrating new drug research and development, raw material production, pharmaceutical preparation production and pharmaceutical circulation. The current employees are more than 2,000 and the total assets are more than 1 billion yuan. At present, the group is centered on Jiangsu Yabang Pharmaceutical Group Co., Ltd., and owns Yabang Pharmaceutical Co., Ltd., Jiangsu Yabang Johnson Pharmaceutical Co., Ltd., Jiangsu Yabang Epson Pharmaceutical Co., Ltd., and Jiangsu Yabang Shengyuan Pharmaceutical Co., Ltd. 6 wholly-owned subsidiaries including Co., Ltd., Changzhou Yabang Pharmaceutical Co., Ltd., Changzhou Yabang Pharmaceutical Research Institute Co., Ltd. After years of scientific research and innovation, Yabang Pharmaceutical has now formed a high-tech specialty covering anti-infective drugs, cardiovascular and cerebrovascular drugs, respiratory and immune system drugs, and has 7 major series, nearly 20 dosage forms, and more than 200 specifications. Product group. A marketing network covering 29 provinces (cities), 40 regions and more than 1,000 marketers across the country has been established.

Sichuan Kelun Pharmaceutical Co., Ltd.

Founded in 1996, Kelun has now formed a "Pin"-shaped architecture operation platform composed of Kelun Pharmaceutical, Chuanning Biotechnology and Kelun Botai, with a total market value of over 100 billion yuan. In 2018, Kelun was named "Manufacturing Single Champion Demonstration Enterprise" for his global advantages in large-capacity injections. Sichuan Kelun Pharmaceutical Co., Ltd. was successfully listed on the Shenzhen Stock Exchange in June 2010, and immediately launched the 10 billion industry investment plan and began to implement the development strategy of "three-in-one developments, innovative growth". The first engine maintains Kelun's leading position in the infusion field through continuous industrial upgrading and variety structure adjustment; the second engine builds from intermediates, raw materials to preparations through innovative development and utilization of high-quality natural resources. The third engine accumulates the ultimate driving force for the everlasting enterprise foundation through the construction of the R&D system and diversified technological innovation. In the field of infusion, Kelun has achieved comprehensive industrial upgrading, and has the profitability of both high-end manufacturing and new materials, occupying a strategic high ground for technological innovation and quality benchmarks. Columbia has established a closed responsibility system from drug research and development, production and manufacturing, logistics and transportation to terminal use to ensure product quality and safety. The leading products have been exported in batches and enjoy a high reputation in more than 50 countries and regions. The stand-up bag® independently developed by Kelun is the first at home and abroad. It has more than 20 patents and has won the National Science and Technology Progress Award. It has higher safety and cost-effectiveness than traditional infusions, and has great application value in reducing energy consumption and environmental protection, representing the direction of development of Chinese infusion products. In the field of antibiotics, the company has established Yili Chuanning Biotechnology Co., Ltd. to produce erythromycin thiocyanate and cephalosporin series intermediates. Through R&D testing, upgrading and optimization, innovative cooperation, and the introduction of advanced domestic and foreign technology equipment, Sichuan Ning has been approved to build a National Environmental Protection Antibiotic Bacterial Slag Harmless Treatment and Resource Utilization Engineering Technology Center, solving the source problems of the antibiotic industry. In December 2022, Chuanning Biotech was successfully listed on the Shenzhen Stock Exchange GEM and entered the field of synthetic biology. Kelun has applied for more than 1,300 invention patents and obtained more than 700 invention patents. He has launched the development of more than 500 major drugs in many diseases such as tumors, bacterial infections, parenteral nutrition, etc.; since 2017, it has been approved for marketing every year. More than 20 items have become the leading generic drug enterprise in China, and has become the leading supplier of national centralized drug procurement with a winning rate of nearly 90%. At the same time, more than ten innovations are used to treat major diseases such as tumors, autoimmunity, inflammation, and metabolism. The drug project is in its clinical stage, with multiple clinical trials being a global multi-center research. Multiple projects work together with European and American partners to deploy global clinical research and are carried out simultaneously in multiple countries including China and Europe and the United States to achieve the synergy of pipelines and technology platforms. Effects, maximize the global value of pipelines.

Shenzhen Neptunus Group Co., Ltd.

Haiwang Group was founded in Shenzhen in 1989. For more than 30 years, the company has focused on the innovative development of the pharmaceutical and health industry, serving the national strategy, serving the health of the whole people, serving the health of the people wholeheartedly, and continuously promoting the innovation-driven development strategy, becoming the industrial chain of China's pharmaceutical and health industry. A large backbone enterprise with relatively complete, strong independent innovation capabilities and outstanding business model innovation capabilities have two listed companies. Guided by the "Healthy China" strategy, the entire pharmaceutical and health industry chain as the foundation, deploy innovation chains around the industrial chain, layout industrial chains around the innovation chain, promote industrial innovation, and build a new health industry ecosystem; to discover and solve people's health pain points As a starting point, we will strive to provide the people with all-round and full-cycle health services. Comprehensive advantages of the entire industrial chain - Aquaman Group relies on the strong resources accumulated in the development of the pharmaceutical and health industry for more than 30 years to create a comprehensive advantage of the entire pharmaceutical and health industry chain. Based on independent innovation, core business segments such as Neptune Bio, Neptune Star, and Neptune Youpin are integrated with each other and complement each other's advantages to create an industrial matrix for the coordinated development of pharmaceutical industry, pharmaceutical commerce, chain retail, health products and Internet medicine. Outstanding innovation capabilities - Aquaman Group has an advanced domestic independent innovation system for pharmaceutical products. It has R&D platforms such as the National Enterprise Technology Center, the National High-Tech Research and Development Plan Results Industrialization Base, the Academician Workstation, and the Postdoctoral Research Workstation. New drug research and development has achieved fruitful results in the fields of anti-tumor, cardiovascular and cerebrovascular, marine drugs, etc., and has achieved major breakthroughs in the research and development of Class I new drugs. The pharmaceutical business network and chain pharmacies spread all over the country - Aquaman Pharmaceutical Business Network is located in more than 20 provinces and cities across the country. Neptune Star pharmacies are distributed in more than 70 large and medium-sized cities across the country, with more than 4,000 direct stores and annual sales exceeding 10 billion. National large-scale health products production and sales system - Haiwang Youpin has 106 registered health food approval documents and 221 registered health food approval documents; 5 large health food production bases, with annual production capacity expected to reach 10 billion yuan, covering the mainstream market The product dosage form has strong production capacity and production and supporting service capabilities. We have accumulated rich resources and experience in product research and development, production, marketing, promotion, consumer education, etc. Aquaman actively promotes the "Aquaman Excellent Products" strategy, is committed to building an efficient health care product operation system, is committed to allowing every Chinese to enjoy nutritional health care, and is committed to creating a price depression for all healthy and nutritious products, so that reasonable value of nutritional health can become The equal power of everyone provides scientific nutrition to hundreds of millions of Chinese people and helps the steady progress of "Healthy China".

Guangzhou Lonst Pharm Co., Ltd.

Chilu is a brand product of Guangzhou Langsheng Pharmaceutical Co., Ltd. Chilu sildenafil citrate tablets are a highly selective type 5 phosphodiesterase inhibitor (PDE-5 inhibitor). Guangzhou Langsheng Pharmaceutical Co., Ltd. was established in 2003 and focuses on the fields of reproductive health drugs, chronic disease drugs, and external drugs. It is a high-tech pharmaceutical company integrating R&D, production and marketing. Langsheng Pharmaceutical's corporate mission is to "make human reproduction healthier". The sales network is spread all over the country, and offline has close strategic cooperation with 80% of the top 100 chains in the country, and online has cooperation with major mainstream e-commerce platforms such as JD.com and Tmall. At the same time, Langsheng Pharmaceutical also founded Langsheng Reproductive Health Research Institute, which serves the public from three dimensions: female reproductive health, male reproductive health and assisted reproductive health, helping consumers to understand their bodies more deeply and avoid accidents. Injury to your own reproductive system.

Viatris Inc.

Viagra generally refers to sildenafil citrate. Sildenafil citrate is a drug with a chemical name of 1-[4-ethoxy-3-[5-(6,7-dihydro-1- Methyl-7-oxo-3-propyl-1H-pyrazolo[4,3d]pyrimidine)]benzenesulfonyl]-4-methylpiperazine citrate, is a white powder. Used to treat penile erectile dysfunction (ED). Contraindications Patients taking any dosage form of nitrate drugs, whether taken regularly or intermittently, are contraindications. It is contraindicated for patients with allergies to any component of sildenafil.

Qilu Pharmaceutical Co., Ltd.

Qianwei is a drug produced by Qilu Pharmaceutical for the treatment of male erectile dysfunction (ED). It was approved for marketing in August 2020 and has three specifications: 50mg, 25mg and 0.1g. Qilu Pharmaceutical aims to safeguard human health, meets social needs as its mission, and relies on advanced science and technology, it is committed to developing and developing drugs that treat common diseases, frequent diseases and many other diseases that seriously endanger human health. The company is headquartered in Jinan City, Shandong Province. It is a large comprehensive modern pharmaceutical enterprise in China. It specializes in the development, production and sales of preparations and raw materials for the treatment of tumors, cardiovascular and cerebrovascular, anti-infection, mental system, nervous system, and ophthalmic diseases. The company has always adhered to the innovative development strategy, with market demand as the core and product innovation as the leader, widely expanded domestic and foreign scientific research and development cooperation, focused on the introduction and cultivation of talents, and built a high-quality scientific research team with professional and effective R&D capabilities. , has successfully developed nearly 100 national new drugs, established a reasonable product line for the company's future development. Many studies have been awarded national and provincial scientific and technological progress awards and have created good social benefits. The company has built production bases for preparations, chemical synthesis, biotechnology, antibiotic fermentation and other production workshops, and fully automatic production lines and other major production equipment and testing instruments are purchased from major professional pharmaceutical equipment manufacturers in the world, antibiotic raw materials, Several products such as cephalosporin raw materials and anti-tumor raw materials have already had leading production capacity and production level. The company has always adhered to the innovative development strategy, with market demand as the core and product innovation as the leader, widely expanded domestic and foreign scientific research and development cooperation, focused on the introduction and cultivation of talents, and built a high-quality scientific research team with strong R&D capabilities. Nearly 100 new drugs have been successfully developed, a reasonable product line under development has been established for the company's future development, and a good social benefit has been created. The company has built a strict and standardized quality control agency and a complete quality assurance system. It is a GMP certified enterprise of the State Food and Drug Administration. Among them, non-sterile raw materials (fermentation, chemical synthesis), sterile raw materials and various preparations have passed the certification of drug regulatory agencies in the United States, the European Union, Australia, the United Kingdom, South Africa and other countries and regions. The company's product structure is scientific and complete, with more than 270 products on the market, with a wide range of therapeutic areas and product series. With excellent product quality and wholehearted service tenet to serve customers, it has established the Qilu brand in the field of medicine. It has a world sales network spread across major provinces and cities across the country and sold to North America, the European Union, Japan, Australia and other places, and has a good service to China and the world present trustworthy sincerity. "The great doctor is sincere and the country is the whole country." The company condenses a unique corporate culture with Qilu characteristics and realizes the common growth of employees and enterprises. While developing rapidly, we have fulfilled all social responsibilities, helped the poor and the needy, and dedicated our love, and demonstrated the development and take-off of China's national pharmaceutical enterprises with brilliant achievements and proud spirit.

Fujian Gelsemium Pharmaceutical Co., Ltd.

Fujian Guangshengtang Pharmaceutical Co., Ltd. was founded in June 2001. It is a national key high-tech enterprise in the antiviral field mainly based on liver drugs, and has five major clinical drugs for anti-hepatitis B virus. The company adheres to the development strategy of transforming from traditional generic drugs to innovative drugs, and continues to introduce and develop first-class innovative drugs and high-end generic drugs. The company has multiple sub-business units, with more than a dozen best-selling varieties covering liver disease, menstruation, cardiovascular, Chinese patent medicine and other fields; the company has been rated as a National Enterprise Technology Center and a demonstration enterprise for intellectual property advantages in China. The company was successfully listed on the Shenzhen Stock Exchange on April 22, 2015 (stock code 300436). Guangshengtang Pharmaceutical’s marketing network covers the whole country, with a layout of “one, two places, and multiple centers”. Keep up with the development trends and trends of international life medicine, adhere to the "innovation strategy, brand strategy, and international strategy", base ourselves in China, and go to the world. The company is headquartered in Fuzhou City, Fujian Province, a well-known "Fuzhou Province". In June 2016, Fuzhou City approved the construction of a national independent innovation demonstration park with the approval of the State Council. Guangshengtang Pharmaceutical Management Headquarters is located in Building 16, the main park, which is only separated from the main urban area of ​​Fuzhou by a river. Haixi Park forms a "one-hour traffic circle" with the airport and the wharf. High-end R&D, technology incubation and headquarters economy are the main positioning of management headquarters.

Guangdong Dongyangguang Science & Technology Holding Co., Ltd.

Yichang Dongyangguang Changjiang Pharmaceutical Co., Ltd. was formerly known as Yichang Changjiang Pharmaceutical Co., Ltd. (hereinafter referred to as "Dongyangguang Pharmaceutical" and "Company") and was established on August 8, 2001 and was restructured into a joint stock company in 2015. Dongyangguang Pharmaceutical is a Chinese pharmaceutical company focusing on the development, production and sales of antiviral, endocrine and metabolic diseases, cardiovascular diseases and other therapeutic fields. It produces, promotes and sells a total of 33 pharmaceutical products in China and has established it in China. Large product distribution network. In March 2006, the licensor of oseltamivir phosphate will grant Shenzhen Dongyangguang Industrial, one of our controlling shareholders, the right to sell oseltamivir phosphate to China and to institutions controlled by the Chinese government. Shenzhen Dongyangguang Industrial also has the right to license the agreement to the company. In the future, the company independently developed oseltamivir phosphate granules for the domestic pediatric patient market and obtained relevant production patents. It is a manufacturer of oseltamivir phosphate granules, thus consolidating its important position in China's anti-influenza virus product market. The company can give priority to obtaining products developed by Yichang Dongyang Sunshine Pharmaceutical Research and Development and its subsidiaries. In terms of the number of patents submitted in China, Yichang Dongyang Sunshine Pharmaceutical R&D and its subsidiary are China's leading drug research institutions with more than [1,200] R&D personnel. Yichang Dongyang Sun Pharmaceutical Research and Development also has a large number of research projects that cooperate with overseas research cooperation institutions and major universities in the Chinese region. Most of the company's directors and senior management team members have professional qualifications or hold important positions in industry associations, such as practicing pharmacists, professors and lecturers from several universities in China, registered auditors and executive directors of Hubei Pharmaceutical Industry Association.

Chengdu Di'ao Pharmaceutical Group Co., Ltd.

Chengdu DiAo Group is a high-tech enterprise founded on August 18, 1988. After more than 6,000 DiAo people's unremitting efforts, it has become a collection of natural medicines, synthetic medicines, genetic engineering medicines, and microbial medicines. A large backbone pharmaceutical enterprise integrating the development of pharmaceutical preparations, a new force with relatively development potential in the mining and energy field. Dio Group currently has four pharmaceutical companies, a pharmaceutical sales company, a cosmetics manufacturer, a health care product (including cosmetics) sales company, a mining and energy company, a real estate company, and a total of 10 subordinate enterprises and holding enterprises, covering an area of ​​land. The area is nearly 400 acres. DiAo Group has the advantages of modern technology, large-scale production, quality and safety testing, high-tech products, and marketing network. It currently has 1,780 scientific and technological personnel, 24 doctoral and postdoctoral students, more than 140 masters, and more than 50,000 square meters of modern production site, production The workshops have passed the national GMP certification. In 2010, the DiAo Xinxuekang production line passed the EU GMP certification. Over the past 30 years, DiAo Group has worked hard to forge ahead with the spirit of "pragmatism, innovation, integrity and dedication", and achieved leapfrog development. The group's net assets have exceeded 7 billion yuan.

Guangdong Tainkang Pharmaceutical Co., Ltd.

Guangdong Taienkang Pharmaceutical Co., Ltd. (hereinafter referred to as "Taienkang"), stock code 301263. Taienkang was established in 1999. Its main business is agency operation and research and development, production, sales of pharmaceutical products, medical devices, sanitary materials, and providing medical technical services and technology transfer. The main products are Hewei Zhenchan Pills and "Wori" Ting" lecithin complex iodine tablets and "Aitingjiu" dapoxetine hydrochloride tablets. Since its establishment, Taienkang has been agents and operated by Weizhen Chan Chan Wan and Wolitin. As the general agent of China, it is fully responsible for customs declaration, inspection, marketing promotion, distributor selection, sales pricing and other work in the Chinese market, and will promote its operations and promotion respectively. It has become a well-known product in the fields of gastrointestinal medicine and ophthalmic medicine in my country. After more than 20 years of marketing promotion, the company has formed a large-scale sales channel network and team. Through strong in-hospital channel control capabilities and innovative drug promotion models, products can quickly achieve sales revenue after they are launched. In 2015, the company established a R&D subsidiary Shandong Huabo Kaisheng Biotechnology Co., Ltd. Based on the R&D strategy of "innovative drug research and development as the top, improved new drugs and biopharmaceuticals as the tower body, and generic drugs as the foundation", a functional auxiliary materials and nano-dose technology platform, a biomacromolecular drug technology platform and generic drugs have been built. Development and consistency evaluation technology platform. The company's independently developed "Aitingjiu" dapoxetine hydrochloride tablets is the "first imitation" in China. Tadalafil has obtained the drug registration approval document and obtained the first clinical trial of docetaxel polymer micelles for injection in China in 2018. Approval and signed a project transfer agreement with Fosun Pharma. In addition, the company also reserves a large number of independent drug research and development projects, among which Praxol Hydrochloride sustained release tablets, ornizolazone injection, and Agatroban injection have submitted drug registration approval applications, and ranibizumab injection is about to apply for clinical application. test. In the next three years, the company expects that the products under development will be approved for listing every year, which will continue to drive the company's product pipeline enrichment and rapid growth in profitability.

Generic

Vardenafil is the generic form of Levitra and is used to treat erectile dysfunction. It is available from various manufacturers and offers similar therapeutic effects to the branded version.

AbbVie Inc.

AndroGel is a testosterone gel used for testosterone replacement therapy in men with low testosterone levels. It is applied topically and absorbed through the skin.

Various Manufacturers

While not specifically an ED drug, testosterone replacement therapy (TRT) is often used alongside or instead of ED treatments. TRT is available from multiple manufacturers in various forms like gels, patches, and injections.

Auxilium Pharmaceuticals

Vitaros is a topical cream containing alprostadil, used for treating erectile dysfunction. It was approved by the FDA in 2013 and offers a non-invasive application method.

Various Manufacturers

Alprostadil is a synthetic version of a naturally occurring hormone that relaxes muscles in the penis, allowing increased blood flow. It is available in various forms including injections and suppositories from different manufacturers.

Upsher-Smith Laboratories

MUSE is a urethral suppository form of alprostadil, which is used to treat erectile dysfunction. It was developed by Upsher-Smith Laboratories and offers an alternative method of administration to oral medications.

Pfizer Inc.

Revatio is the brand name for sildenafil citrate when used for pulmonary arterial hypertension (PAH). It was originally developed under the Viagra brand but later received separate approval for PAH treatment.

Vivus Inc.

Stendra (avanafil) is a relatively newer addition to the market, approved by the FDA in

Bayer AG

Levitra, also known as vardenafil, is produced by Bayer AG and GlaxoSmithKline. It is known for its rapid onset of action and is available in various formulations.